Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience

Outcomes of melphalan 140 mg/m2 followed by autologous stem cell transplantation in multiple myeloma patients with co‐morbidities: Single‐centre experience

Abstract High‐dose melphalan followed by stem cell rescue is the standard consolidative therapy for transplant‐eligible patients with multiple myeloma (MM) in the United Kingdom. A melphalan dose of 200 mg/m2 (Mel200) is considered the “gold standard” for autologous stem cell transplant (ASCT) condi...

Full description

Saved in:
Bibliographic Details
Main Authors: Dario Melotti, Samir Asher, Ethan Troy‐Barnes, George Nesr, William Wilson, Marquita Camilleri, Rakesh Popat, Ke Xu, Neil Rabin, Jonathan Sive, Xenofon Papanikolaou, Lydia Lee, Annabel McMillan, Kwee Yong, Chara Kyriakou
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:eJHaem
Subjects:
haematology
multiple myeloma
transplantation
Online Access:https://doi.org/10.1002/jha2.977
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items